Drug-induced side effects affecting the gastrointestinal tract

Expert Opinion on Drug Safety

Volumn 5, Issue 4, 2006, Pages 585-592

  Leong, Rupert W L ^a   Chan, Francis K L ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Aspirin; Diaphragm; Haemorrhage; NSAID; Oesophagitis; Perforation; Ulcer

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; ALLOPURINOL; ANESTHETIC AGENT; ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CORTICOSTEROID DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; FERROUS SULFATE; IMATINIB; METOPROLOL; NICOTINE; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; POTASSIUM CHLORIDE; PROTON PUMP INHIBITOR; QUINIDINE; RISEDRONIC ACID; SEROTONIN ANTAGONIST; SULFONAMIDE; TETRACYCLINE; THEOPHYLLINE; TICLOPIDINE; UNINDEXED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; BLOODY DIARRHEA; BODY WEIGHT DISORDER; BONE PAIN; CAPSULE ENDOSCOPY; CLINICAL TRIAL; COLLAGENOUS COLITIS; COLON DISEASE; COLON OBSTRUCTION; COLON PERFORATION; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DEFECATION DISORDER; DIARRHEA; DIGESTIVE SYSTEM INJURY; DIGESTIVE SYSTEM PERFORATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; DUODENUM DISEASE; DYSPEPSIA; DYSPHAGIA; ENTERITIS; ENTEROPATHY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGITIS; ESOPHAGUS HEMORRHAGE; ESOPHAGUS PERFORATION; ESOPHAGUS STRICTURE; ESOPHAGUS ULCER; GASTRITIS; GASTRODUODENAL ULCER; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GINGIVA HYPERPLASIA; GINGIVA OVERGROWTH; GRAFT REJECTION; HEALTH CARE COST; HEART MUSCLE ISCHEMIA; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IRON DEFICIENCY ANEMIA; ISCHEMIC COLITIS; LICHEN PLANUS; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; LYMPHOCYTIC COLITIS; MICROSCOPIC COLITIS; MOUTH DISEASE; MUCOCUTANEOUS CANDIDIASIS; NAUSEA; ODYNOPHAGIA; OROPHARYNX CANDIDIASIS; PANCREATITIS; PATHOGENESIS; PATIENT EDUCATION; PEPTIC ULCER; PEPTIC ULCER BLEEDING; PERITONITIS; PRESCRIPTION; PSEUDOMEMBRANOUS COLITIS; RETROSTERNAL PAIN; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SLOW RELEASE FORMULATION; SQUAMOUS CELL CARCINOMA; STEVENS JOHNSON SYNDROME; STOMACH ADENOCARCINOMA; STOMACH DISEASE; STOMACH EROSION; STOMACH HEMORRHAGE; STOMACH MUCOSA INJURY; STOMACH ULCER; STOMATITIS; TELANGIECTASIA; ULCER PERFORATION; VASCULITIS; VASOSPASM; VOMITING; WEIGHT REDUCTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BONE DENSITY CONSERVATION AGENTS; COLITIS; COLON; CYCLOSPORINE; DIPHOSPHONATES; DUODENAL OBSTRUCTION; DUODENAL ULCER; ESOPHAGITIS; ESOPHAGUS; GINGIVAL HYPERPLASIA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINE, SMALL; MOUTH; STOMACH ULCER;

EID: 33749130839     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.5.4.585     Document Type: Review

References (67)

1. WOLFE MM, LICHTENSTEIN DR, SINGH G: Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N. Engl. J. Med. (1999) 340:1888-1899.
2. ANDERSON JG: A systems approach to preventing adverse drug events. Stud. Health Technol. Inform. (2003) 92:95-102.
3. RODEN DM: Principals of Clinical Pharmacology. In: Harrison's Principles of Internal Medicine (16th edn). Kasper DL (Ed.), McGraw-Hill Co., Inc. USA (2005):23.
4. PRICE AB: Pathology of drug-associated gastrointestinal disease. Br. J. Clin. Pharmacol. (2005) 56:477-482
5. EGGERATH J, ENGLISH H, LEICHTER JW: Drug-associated gingival enlargement: case report and review of aetiology, management and evidence-based outcomes of treatment. J. N. Z. Soc. Periodontol. (2005) 88:7-14.
6. LIN MS, DAI YS, PWU RF, CHEN YH, CHANG NC: Risk estimates for drugs suspected of being associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study. Int. Med. J. (2005) 35:188-190.
7. SAADEH CE: Chemotherapy- and radiotherapy-induced oral mucositis: review of preventive strategies and treatment. Pharmacotherapy (2005) 25:540-554.
8. ENG J, SABANATHAN S: Drug-induced esophagitis. Am. J. Gastroenterol. (1991) 86:1127.
9. DE GROEN PC, LUBBE DF, HIRSCH LJ et al.: Esophagitis associated with the use of alendronate. N. Engl. J. Med. (1996) 335(14):1016-1021.
10. TAGGART H, BOLOGNESE MA, LINDSAY R et al.: Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin. Proc. (2002) 77(3):262-270.
11. NAYLOR G, DAVIES MH: Oesophageal stricture associated with alendronic acid. Lancet (1996) 348(9033):1030-1031.
12. ISHIKAWA H, IWAKIRI K, SUGIURA T, KOBAYASHI M: Effect of nifedipine administration (10 mg) on esophageal acid exposure time. J. Gastroenterol. (2000) 35:43-46.
13. VAUGHAN TL, FARROW DC, HANSTEN PD et al.: Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux. Cancer Epidemiol. Biomarkers Prev. (1998) 7:749-756.
14. LICHTENSTEIN DR, SYNGAL S, WOLFE MM: Nonsteroidal antiinflammatory drugs and the gastrointestinal tract: the double-edged sword. Arthritis Rheum. (1995) 38:5-18.
15. HUI AJ, LEONG RW, CHAN FK: Gastric ulcer. In: Encylopedia of Gastroenterology (1st edn), Johnson Leonard R (Ed.), Academic Press, Memphis, USA (2004):157-162.
16. VANCE JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. (1971) 231:232-235.
17. FUNK CD: Prostaglandins and leukotrienes: advances in eicosanoid biology. Science (2001) 294:1871-1875.
18. BERTOLINI A, OTTANI A, SANDRINI M: Dual acting anti-inflammatory drugs: a reappraisal. Pharmacol. Res. (2001) 44:437-450.
19. EMERY P, ZEIDLER H, KVIEN TK et al.: Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet (1999) 354:2106-2111.
20. HIPPISLEY-COX J, COUPLAND C, LOGAN R: Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. Br. Med. J. (2005) 331:1310-1316.
21. MUKHERJEE D, NISSEN SE, TOPOL EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA (2001) 286:954-959.
22. YEOMANS ND, LANAS AI, TALLEY NJ et al.: Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment. Pharmacol. Ther. (2005) 22:795-801.
23. WEAVER GA, HARPER RL, STOREY JA, JENKINS PL, MERRELL NB: Nonsteroidal antiinflammatory drugs are associated with gastric outlet obstruction. J. Clin. Gastroenterol. (1995) 20:196-198.
24. SINGH G, TRIADAFILOPOULUS G: Epidemiology of NSAID-induced GI complications. J. Rheumatol. (1999) 26(Suppl. 26): 18-24.
25. ARMSTRONG CP, BLOWER AL: Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut (1987) 28:527-532.
26. LANAS A, PEREZ-AISA MA, FEU F et al.: A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am. J. Gastroenterol. (2005) 100:1685-1693.
27. PATRONO C: Aspirin: new cardiovascular uses for an old drug. Am. J. Med. (2001) 110(1A):62S-65S
28. NO AUTHORS LISTED: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet (1996) 348:1329-1339.
29. CHAN FK, CHING JY, HUNG LC et al.: Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N. Engl. J. Med. (2005) 352:238-244.
30. SOLOMON DH, GLYNN RJ, BOHN R, LEVIN R, AVORN J: The hidden cost of nonselective nonsteroidal antiinflammatory drugs in older patients. J. Rheumatol. (2003) 30:792-798.
31. SINGH C, RAMEY DR, TERRY R, KHRAISHI M, TRIADAFILOPOULOS G: NSAID-related effects on the GI tract: an ever widening spectrum. Arthritis Rheum. (1997) 40(Suppl.):S93-S93.
32. RAHME E, JOSEPH L, KONG SX, WATSON DJ, LELORIER J: Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients. Br. J. Clin. Pharmacol. (2001) 52:185-192.
33. TALLEY NJ, EVANS JM, FLEMING KC, HARMSEN WS, ZINSMEISTER AR, MELTON LJ: Nonsteroidal anti-inflammatory drugs and dyspepsia in the elderly. Dig. Dis. Sci. (1995) 40:1345-1350.
34. SINGH G, RAMEY DR, MORFELD D, SHI H, HATOUM HT, FRIES JF: Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis: a prospective observational cohort study. Arch. Intern. Med. (1996) 156:1530-1536.
35. LARKAI EN, SMITH JL, LIDSKY MD, GRAHAM DY: Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic steroidal anti-inflammatory drug use. Am. J. Gastroenterol. (1987) 82:1153-1158.
36. SCHEIMAN JM, YEOMANS ND, TALLEY NJ et al.: Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am. J. Gastroenterol. (2006) 101:1-110.
37. CHAN FK, HUNG LC, SUEN BY et al.: Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterol. (2004) 127:1038-1043.
38. LEE KK, YOU JH, HO JT et al.: Economic analysis of celecoxib versus diclofenac plus omeprazole for the treatment of arthritis in patients at risk of ulcer disease. Aliment. Pharmacol. Ther. (2003) 18:217-222
39. YOU JH, LEE KK, CHAN TY, LAU WH, CHAN FK: Arthritis treatment in Hong Kong-cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents. Aliment. Pharmacol. Ther. (2002) 16:2089-2096.
40. LEONG RW, CHAN FK, SUNG JJ: Helicobacter pylon and nonsteroidal ann-inflammatory drugs. Approaching the end of the controversy in the new millennium, or room for more debate? J. Gastroenterol. (2001) 36:731-739.
41. PAPATHEODORIDIS GV, SOUGIOULTZIS S, ARCHIMANDPRITIS AJ: Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. Clin. Gastroenterol. Hepatol. (2006) 4:130-42.
42. CHAN FK, GRAHAM DY: Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications-review and recommendations based on risk assessment. Aliment. Pharmacol. Ther. (2004) 19:1051-1061.
43. FORTUN PJ, HAWKEY CJ: Nonsteroidal antiinflammatory drugs and the small intestine. Curr. Opin. Gastroenterol. (2005) 21:169-175.
44. GOLDSTEIN JL, EISEN GM, LEWIS B et al.: Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin. Gastroenterol. Hepatol. (2005) 3:133-141.
45. GRAHAM DY, OPEKUN AR, WILLINGHAM FF, QURESHI WA: Visible small-intestinal mucosal injury in chronic NSAID users. Clin. Gastroenterol. Hepatol. (2005) 3:55-59.
46. YOUSFI MM, DE PETRIS G, LEIGHTON JA et al.: Diaphragm disease after use of nonsteroidal anti-inflammatory agents: first report of diagnosis with capsule endoscopy. J. Clin. Gastroenterol. (2004) 38:686-691.
47. REUTER BK, DAVIES NM, WALLACE JL: Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterol. (1997) 112:109-117.
48. BRETT MA, BUSCHER G, ELLRICH E et al.: Nabumetone evidence for the lack of enterohepatic circulation of the active metabolite 6-MNA in humans. Drugs (1990) 40(Suppl. 5):67-70.
49. SOMASUNDARAM S, SIGTHORSSON G, SIMPSON RJ et al.: Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat. Aliment. Pharmacol. Ther. (2000) 14:639-650
50. SATOH H, GUTH PH, GROSSMAN MI: Role of bacteria in gastric ulceration produced by indomethacin in the rat: cytoprotective action of antibiotics. Gastroenterol. (1983) 84:483-489.
51. ISHIHARA Y, OKABE S: Effects of cholestyramine and synthetic hydrotalcite on acute gastric or intestinal lesion formation in rats and dogs. Dig. Dis. Sci. (1981) 26:553-560.
52. THIEFIN G, BEAUGERIE L: Toxic effects of nonsteroidal antiinflammatory drugs on the small bowel, colon, and rectum. Joint Bone Spine (2005) 72:286-294.
53. SINGH G: Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am. J. Med. (1998) 105:31S-38S.
54. LAINE L, CONNORS LG, REICIN A et al.: Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterol. (2003) 124:288-292.
55. HALTER F, WEBER B, HUBER T, EIGENMANN F, FREY MP, RUCHTI C: Diaphragm disease of the ascending colon. Association with sustained-release diclofenac. J. Clin. Gastroenterol. (1993) 16:74-80.
56. MONAHAN DW, STARNES EC, PARKER AL: Colonic strictures in a patient on long-term non-steroidal anti-inflammatory drugs. Gastrointest. Endosc. (1992) 38:385-388.
57. SMYTH RL, VAN VELZEN D, SMYTH AR, LLOYD DA, HEAF DP: Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes. Lancet (1994) 343:85-86.
58. RIDDELL RH, TANAKA M, MAZZOLENI G: Non-steroidal anti-inflammatory drugs as a possible cause of collagenous colitis: a case-control study. Gut (1992) 33:683-686.
59. BEAUGERIE L, LUBOINSKI J, BROUSSE N et al.: Drug induced lymphocytic colitis. Gut (1994) 35:426-428.
60. YANG RD, HAN MW, MCCARTHY JH: Ischaemic colitis in a crack abuser. Dig. Dis. Sci. (1991) 36:238-240.
61. FRIEDEL D, THOMAS R, FISHER RS: Ischemic colitis during treatment with alosetron. Gastroenterol. (2001) 120:557-560.
62. HASLER WL, SCHOENFELD P: Safety profile of tegaserod, a 5-HT4 receptor agonist, for the treatment of irritable bowel syndrome. Drug Saf. (2004) 27:619-631.
63. BIRKS J: Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst. Rev. (2006) 1:CD005593.
64. HARP JB: Orlistat for the long-term treatment of obesity. Drugs Today (1999) 35:139-145.
65. BAILLIE-JOHNSON HR: Octreotide in the management of treatment-related diarrhoea. Anti-Cancer Drugs (1996) 7(Suppl. 1):11-15.
66. RAMPTON DS, SLADEN GE: Relapse of ulcerative proctocolitis during treatment with non-steroidal anti-inflammatory drugs. Postgrad. Med. J. (1981) 57:297-299.
67. BIANCONE L, TOSTI C, GEREMIA A et al.: Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial. Aliment. Pharmacol. Ther. (2004) 19:755-764.